Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting

Beuselinck, Benoit; Job, Sylvie; Becht, Etienne; Karadimou, Alexandra; Verkarre, Virginie; Couchy, Gabrielle; Giraldo, Nicolas; Rioux-Leclercq, Nathalie; Molinié, Vincent; Sibony, Mathilde; Elaidi, Reza; Teghom, Corinne; Patard, Jean-Jacques; Méjean, Arnaud; Fridman, Wolf Herman; Sautès-Fridman, Catherine; de Reyniès, Aurélien; Oudard, Stéphane; Zucman-Rossi, Jessica

doi:10.1158/1078-0432.CCR-14-1128

Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting

Author:

Beuselinck, Benoit

Job, Sylvie ; Becht, Etienne ; Karadimou, Alexandra ; Verkarre, Virginie ; Couchy, Gabrielle ; Giraldo, Nicolas ; Rioux-Leclercq, Nathalie ; Molinié, Vincent ; Sibony, Mathilde ; Elaidi, Reza ; Teghom, Corinne ; Patard, Jean-Jacques ; Méjean, Arnaud ; Fridman, Wolf Herman ; Sautès-Fridman, Catherine ; de Reyniès, Aurélien ; Oudard, Stéphane ; Zucman-Rossi, Jessica

Keywords:

Science & Technology, Life Sciences & Biomedicine, Oncology, C-REACTIVE PROTEIN, INTERFERON-ALPHA, TARGETED THERAPY, POOR SURVIVAL, CANCER, EXPRESSION, DYNAMICS, DEFINES, GAP, Angiogenesis Inhibitors, Antineoplastic Agents, Carcinoma, Renal Cell, Disease-Free Survival, Drug Resistance, Neoplasm, Female, Gene Expression Profiling, Humans, Indoles, Kidney Neoplasms, Male, Mutation, Pyrroles, Sunitinib, Treatment Outcome, Vascular Endothelial Growth Factor Receptor-2, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, 3202 Clinical sciences, 3211 Oncology and carcinogenesis

Abstract:

Selecting patients with metastatic clear-cell renal cell carcinoma (m-ccRCC) who might benefit from treatment with targeted tyrosine kinase inhibitors (TKI) is a challenge. Our aim was to identify molecular markers associated with outcome in patients with m-ccRCC treated with sunitinib.